VA Risk Stratification in Dilated Cardiomyopathy
Definition
Risk stratification for ventricular arrhythmias (VA) and sudden cardiac death (SCD) in non-ischaemic dilated cardiomyopathy (DCM) is the process of identifying which patients are at high enough arrhythmic risk to benefit from implantable cardioverter-defibrillator (ICD) implantation. LVEF ≤35% has been the traditional threshold, but this criterion — derived from ischaemic disease — is increasingly recognized as insufficient for non-ischaemic DCM.
Key Concepts
Annual Event Rate and Baseline Risk
- The crude annual rate of sustained VA (sustained VT, VF, resuscitated SCD, or appropriate ICD discharge) in DCM is approximately 4.5% (meta-analysis, 55 studies, 11,451 patients, mean follow-up 3.7 years). (sources/VA-DCM-Sammani-2020, high)
- This event rate underscores the importance of ICD consideration in this population. (sources/VA-DCM-Sammani-2020, high)
Pooled Risk Predictors (Meta-Analysis Data)
Key pooled hazard ratios from the largest VA-specific DCM meta-analysis (Sammani 2020):
- LGE presence on CMR: HR 5.55 [4.02–7.67] — strongest single predictor (sources/VA-DCM-Sammani-2020, high)
- Prior sustained VA: HR 4.15 [1.32–13.02] — high heterogeneity (I²=93%) (sources/VA-DCM-Sammani-2020, high)
- Hypertension: HR 1.95 [1.26–3.00] (sources/VA-DCM-Sammani-2020, high)
- LVEF per 10% decrease (echocardiography only): HR 1.45 [1.19–1.78] — significant only when measured by echo, not when CMR and echo are pooled (sources/VA-DCM-Sammani-2020, high)
- LV dilatation (LVEDV/LVESV per 10 mL/m²): HR 1.10 for both parameters — small but significant (sources/VA-DCM-Sammani-2020, high)
- Younger age (per 10-year increase): HR 0.82 [0.74–1.00] — younger age confers higher risk (sources/VA-DCM-Sammani-2020, high)
Non-Pooled Predictors (Systematic Review Signal)
- Non-sustained VT: 9 of 14 studies reported significantly increased arrhythmic risk; could not be pooled due to missing HRs. Supported by AMIOVIRT and DEFINITE trial populations. (sources/VA-DCM-Sammani-2020, high)
- T-wave alternans (TWA): HR 6.5 [2.46–17.14]; clinical utility limited by poor standardization. (sources/VA-DCM-Sammani-2020, high)
- Genetic mutations — PLN, LMNA, FLNC: Each independently associated with VA risk in DCM; FLNC truncating variants associated with VA/SCD in 82% of patients in cohort studies. (sources/VA-DCM-Sammani-2020, high)
Non-Significant Predictors
- Male sex (trend only), NYHA class, family history of DCM, AF, LBBB, QRS duration, LVEF <30% or <35% as categorical thresholds, signal-averaged ECG, standard biomarkers (BNP, ANP, eGFR). (sources/VA-DCM-Sammani-2020, high)
LVEF Limitations
- The standard ICD threshold of LVEF ≤35% is derived from ischaemic disease populations. The DANISH trial showed no all-cause mortality benefit in non-ischaemic DCM. (sources/VA-SCD-ESC-2022, (sources/VA-DCM-Sammani-2020, high)
- LVEF as a continuous echocardiographic variable predicts VA (HR 1.45 per 10%), but categorical cutoffs (LVEF <30% or <35%) are non-significant in pooled analysis, suggesting LVEF should not be the sole criterion. (sources/VA-DCM-Sammani-2020, high)
- Genotype-specific ICD criteria now extended to LVEF 35–50% range for high-risk genotypes (PLN, LMNA, FLNC, RBM20) with additional risk factors. (sources/VA-SCD-ESC-2022)
Multi-Parameter Risk Stratification (Current Guidelines)
- ESC 2022 multi-risk-factor ICD threshold (Class IIa): ICD in DCM/HNDCM with LVEF <50% AND ≥2 of: syncope, LGE on CMR, inducible SMVT at PES, pathogenic mutation in LMNA/PLN/FLNC/RBM20. (sources/VA-SCD-ESC-2022)
- ESC CMP 2023: Genotype-guided ICD considered in PLN, LMNA, FLNC, RBM20, DES, TMEM43 carriers with LVEF >35% and additional risk factors (NSVT, syncope, LGE). (sources/esc-cmp-2023)
- Genotype-specific calculators: LMNA risk-VTA calculator (lmna-risk-vta.fr); PLN p.Arg14del risk calculator endorsed for ICD decisions in respective mutation carriers. (sources/esc-cmp-2023)
Future Directions
- A dedicated DCM-VA risk calculator analogous to HCM Risk-SCD and the ARVC risk model is needed.
- Such a model should incorporate: younger age, hypertension, prior (non-)sustained VA, LVEF (echo), LV dilatation, LGE, genetic mutations (PLN, LMNA, FLNC), and sex.
- Competing risk analysis (VA vs. HF-related outcomes) is essential for accurate real-world risk estimation. (sources/VA-DCM-Sammani-2020, high)
Contradictions / Open Questions
- LVEF echo vs. CMR discordance: LVEF predicts VA only when measured by echocardiography (HR 1.45 significant), but not when CMR and echo are pooled (HR 1.30 non-significant). The modality-specific difference may reflect population-selection differences or systematic underestimation of LVEF by echo in DCM. This has practical implications for how LVEF thresholds are applied in ICD guidelines. (sources/VA-DCM-Sammani-2020, high)
- ESC 2022 dual ICD thresholds: Two Class IIa criteria (standard LVEF ≤35% and multi-factor LVEF <50%) coexist without guidance on which applies when a patient qualifies under both. (sources/VA-SCD-ESC-2022)
- Quality of evidence is moderate: Crude (unadjusted) HRs are pooled; confounder adjustment was limited in most primary studies. The true independent contribution of each risk factor remains uncertain. (sources/VA-DCM-Sammani-2020, high)
- Competing risks not modelled: DCM patients face both arrhythmic death and HF-related death/transplantation. Competing risks modelling may change individual risk estimates substantially. (sources/VA-DCM-Sammani-2020, high)
Connections
- Related to entities/DCM
- Related to entities/LMNA
- Related to entities/PLN
- Related to entities/FLNC
- Related to entities/NDLVC
- Related to concepts/Late-Gadolinium-Enhancement
- Related to concepts/Sudden-Cardiac-Death
- Related to concepts/HCM-Risk-SCD
- Related to concepts/Cascade-Family-Screening